

MMP-13 inhibitors

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 21	IPC search and display fields enhanced in CA/Caplus with the IPC reform
NEWS	4	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2
NEWS	5	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	6	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	7	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	8	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	9	JAN 30	Saved answer limit increased
NEWS	10	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS	11	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	12	FEB 22	Status of current WO (PCT) information on STN
NEWS	13	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	14	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	15	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	16	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	17	FEB 28	TOXCENTER reloaded with enhancements
NEWS	18	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	19	MAR 01	INSPEC reloaded and enhanced
NEWS	20	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	21	MAR 08	X.25 communication option no longer available after June 2006
NEWS	22	MAR 22	EMBASE is now updated on a daily basis
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

MMP-13 inhibitors

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:46:00 ON 30 MAR 2006

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:46:24 ON 30 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAR 2006 HIGHEST RN 878378-71-3

DICTIONARY FILE UPDATES: 28 MAR 2006 HIGHEST RN 878378-71-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\valdecxib.str

MMP-13 inhibitors



```

chain nodes :
12 19 20 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 13 14 15 16 17 18
chain bonds :
6-7 10-12 11-13 16-19 19-20 19-21 19-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 13-14 13-18 14-15
15-16 16-17 17-18
exact/norm bonds :
7-8 7-11 8-9 9-10 10-11 16-19 19-20 19-21 19-22
exact bonds :
6-7 10-12 11-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:CLASS

```

L1 STRUCTURE UPLOADED

=> s L1

SAMPLE SEARCH INITIATED 10:46:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 47 TO ITERATE


100.0% PROCESSED 47 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 529 TO 1351
PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1


MMP-13 inhibitors

=> d L1 107
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d L1 1-7
L1 HAS NO ANSWERS
L1 STR



MMP-13 inhibitors


Structure attributes must be viewed using STN Express query preparation.

=> d L2 1-7

L2 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 848124-98-1 REGISTRY
ED Entered STN: 08 Apr 2005
CN Benzamide, 2-chloro-5-[[2-[(2-hydroxyethyl)amino]ethoxy)methyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-, mixt. with 4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide (9CI) (CA INDEX NAME)
MF C23 H33 Cl N2 O3 . C16 H14 N2 O3 S
CI MXS
SR CA
LC STN Files: CA, CAPLUS


CM 1

CRN 345304-10-1
CMF C23 H33 Cl N2 O3



CM 2

CRN 181695-72-7
CMF C16 H14 N2 O3 S




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 603151-46-8 REGISTRY
ED Entered STN: 13 Oct 2003
CN Benzenesulfonamide, 4-[5-methyl-3-[3-(methylsulfonyl)phenyl]-4-isoxazolyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H16 N2 O5 S2

MMP-13 inhibitors


SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 501093-54-5 REGISTRY
ED Entered STN: 01 Apr 2003
CN Benzenesulfonamide, 4-[3-(3-(4-methylbenzenesulfonyl)-5-methyl-4-isoxazolyl)- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C16 H14 N2 O4 S
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473311-73-8 REGISTRY
ED Entered STN: 12 Nov 2002
CN Benzenesulfonamide, 4-[3-(3-(3,5-dimethylphenyl)-5-methyl-4-isoxazolyl)-2,5-difluoro- (9CI) (CA INDEX NAME)

MMP-13 inhibitors

OTHER NAMES:

CN 2,5-Difluoro-4-[3-(3,5-dimethylphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide
FS 3D CONCORD
MF C18 H16 F2 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473308-32-6 REGISTRY
ED Entered STN: 12 Nov 2002
CN Benzenesulfonamide, 4-[3-(3-chloro-4-methoxyphenyl)-5-methyl-4-isoxazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2,6-Difluoro-4-[3-(3-chloro-4-methoxyphenyl)-5-methylisoxazol-4-yl]benzenesulfonamide
FS 3D CONCORD
MF C17 H13 Cl F2 N2 O4 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)


MMP-13 inhibitors

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 473308-00-8 REGISTRY
ED Entered STN: 12 Nov 2002
CN Benzenesulfonamide, 4-[3-(4-chlorophenyl)-5-methyl-4-isoxazolyl]-2,6-difluoro- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2,6-Difluoro-4-[3-(4-chlorophenyl)-5-methylisoxazol-4-yl]benzenesulfonamide
FS 3D CONCORD
MF C16 H11 Cl F2 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2006 ACS on STN
RN 219679-65-9 REGISTRY
ED Entered STN: 14 Feb 1999
CN Benzoic acid, 6-[4-[4-(aminosulfonyl)phenyl]-5-methyl-3-isoxazolyl]-2,3-dichloro- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H12 Cl2 N2 O5 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



MMP-13 inhibitors

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	14.62	14.83

FILE 'REGISTRY' ENTERED AT 10:48:11 ON 30 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAR 2006 HIGHEST RN 878378-71-3
DICTIONARY FILE UPDATES: 28 MAR 2006 HIGHEST RN 878378-71-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> S 181695-72-7/RN

L3 1 181695-72-7/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L3 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS

MMP-13 inhibitors

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L3 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 181695-72-7 REGISTRY

CN Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4-(5-Methyl-3-phenylisoxazol-4-yl)benzenesulfonamide

CN Bextra

CN SC 65872

CN Valdecoxib

CN Valecoxib

FS 3D CONCORD

MF C16 H14 N2 O3 S

CI COM

SR CA

LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CSCHEM, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)


DT.CA Caplus document type: Conference; Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

534 REFERENCES IN FILE CA (1907 TO DATE)

23 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

538 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND

SET COMMAND COMPLETED

=>

MMP-13 inhibitors

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.34	17.17

FILE 'REGISTRY' ENTERED AT 10:48:38 ON 30 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAR 2006 HIGHEST RN 878378-71-3
DICTIONARY FILE UPDATES: 28 MAR 2006 HIGHEST RN 878378-71-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> SET TERMSET E#

SET COMMAND COMPLETED

=> DEL SEL Y

=> SEL L3 1 RN

E1 THROUGH E1 ASSIGNED

=> S E1/RN

L4 1 181695-72-7/RN

=> SET TERMSET LOGIN

SET COMMAND COMPLETED

MMP-13 inhibitors

=> FIL USPATFULL

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.52	17.69

FILE 'USPATFULL' ENTERED AT 10:48:43 ON 30 MAR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 30 Mar 2006 (20060330/PD)
FILE LAST UPDATED: 30 Mar 2006 (20060330/ED)
HIGHEST GRANTED PATENT NUMBER: US7020895
HIGHEST APPLICATION PUBLICATION NUMBER: US2006070159
CA INDEXING IS CURRENT THROUGH 28 Mar 2006 (20060328/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 30 Mar 2006 (20060330/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006

=> S L4

L5 311 L4

=> S L5 AND 1990<=PY<=2001 AND (PATENT)/DT AND (ENGLISH)/LA
1687978 1990<=PY<=2001
4417602 (PATENT)/DT
4417602 (ENGLISH)/LA

L6 12 L5 AND 1990<=PY<=2001 AND (PATENT)/DT AND (ENGLISH)/LA

=> DIS L6 1- TRIAL

YOU HAVE REQUESTED DATA FROM 12 ANSWERS - CONTINUE? Y/(N):Y

L6 ANSWER 1 OF 12 USPATFULL on STN

AN 2003:67775 USPATFULL

TI Method of treating neurodegenerative diseases

INCL INCLM: 514/315.000

INCLS: 514/408.000; 514/438.000; 514/461.000

NCL NCLM: 514/315.000

NCLS: 514/408.000; 514/438.000; 514/461.000

IC [7]

ICM A61K031-445

ICS A61K031-40; A61K031-38; A61K031-34

IPCI A61K0031-445 [ICM,7]; A61K0031-40 [ICS,7]; A61K0031-38 [ICS,7];
A61K0031-34 [ICS,7]

IPCR A61K0031-34 [I,A]; A61K0031-34 [I,C]; A61K0031-38 [I,A];

A61K0031-38 [I,C]; A61K0031-40 [I,A]; A61K0031-40 [I,C];

A61K0031-55 [I,A]; A61K0031-55 [I,C]

GI	SECTION	PAGES	FORMAT	SIZE
	FRONT PAGE	1	PAGE.FP	38K
	DESCRIPTION	2-5	PAGE.DESC	401K
	CLAIMS	5-6	PAGE.CLM	134K
	COMPLETE	1-6	PAGE.ALL	480K

Use PAGE(n) to retrieve a specific page

L6 ANSWER 2 OF 12 USPATFULL on STN

AN 2001:215073 USPATFULL

TI Treatment of heart disease with cox-2 inhibitors

INCL INCLM: 514/343.000

INCLS: 514/378.000; 514/403.000; 514/473.000

NCL NCLM: 514/343.000

NCLS: 514/378.000; 514/403.000; 514/473.000

MMP-13 inhibitors

IC [7]
ICM A61K031-44
ICS A61K031-42; A61K031-415; A61K031-34; A61P009-04
IPCI A61K0031-44 [ICM,7]; A61K0031-42 [ICS,7]; A61K0031-415 [ICS,7];
A61K0031-34 [ICS,7]; A61P0009-04 [ICS,7]
IPCR A61K0031-00 [I,A]; A61K0031-00 [I,C]; A61K0031-34 [I,A];
A61K0031-34 [I,C]; A61K0031-365 [I,A]; A61K0031-365 [I,C];
A61K0031-415 [I,A]; A61K0031-415 [I,C]; A61K0031-42 [I,A];
A61K0031-42 [I,C]; A61K0031-44 [I,A]; A61K0031-44 [I,C];
A61K0031-4427 [I,C]; A61K0031-444 [I,A]; A61K0045-00 [I,C];
A61K0045-06 [I,A]

PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 3 OF 12 USPATFULL on STN

AN 2001:205933 USPATFULL

TI Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions
and methods of use

INCL INCLM: 514/361.000

INCLS: 548/127.000; 548/360.100; 548/250.000; 514/249.000

NCL NCLM: 514/326.000; 514/361.000

NCLS: 514/378.000; 514/406.000; 546/209.000; 548/247.000; 548/248.000;
548/375.100; 548/561.000; 514/249.000; 548/127.000; 548/250.000;
548/360.100

IC [7]
ICM A61K031-495
ICS A61K031-50; A01N043-58; A01N043-60; A61K031-41; A01N043-82
IPCI A61K0031-495 [ICM,7]; A61K0031-50 [ICS,7]; A01N0043-58 [ICS,7];
A01N0043-60 [ICS,7]; A61K0031-41 [ICS,7]; A01N0043-82 [ICS,7]
IPCI-2 C07D0207-325 [ICM,7]; C07D0231-06 [ICS,7]; A61K0031-40 [ICS,7];
A61K0031-415 [ICS,7]
IPCR C07C0317-00 [I,C]; C07C0317-46 [I,A]; C07C0381-00 [I,A];
C07C0381-00 [I,C]; C07D0207-00 [I,C]; C07D0207-333 [I,A];
C07D0209-00 [I,C]; C07D0209-12 [I,A]; C07D0209-18 [I,A];
C07D0231-00 [I,C]; C07D0231-12 [I,A]; C07D0231-14 [I,A];
C07D0233-00 [I,C]; C07D0233-54 [I,A]; C07D0237-00 [I,C];
C07D0237-14 [I,A]; C07D0261-00 [I,C]; C07D0261-08 [I,A];
C07D0263-00 [I,C]; C07D0263-20 [I,A]; C07D0311-00 [I,C];
C07D0311-12 [I,A]; C07D0413-00 [I,C]; C07D0413-12 [I,A];
C07D0471-00 [I,C]; C07D0471-04 [I,A]

PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 4 OF 12 USPATFULL on STN

AN 2001:185277 USPATFULL

TI Protected forms of a combination of pharmacologically active agents and
uses therefor

INCL INCLM: 514/159.000

INCLS: 514/161.000; 514/569.000; 514/570.000; 514/567.000; 514/629.000;
514/158.000

NCL NCLM: 514/159.000

NCLS: 514/158.000; 514/161.000; 514/567.000; 514/569.000; 514/570.000;
514/629.000

IC [7]
ICM A01N037-36
ICS A01N043-00; A01N051-00; A01N037-10; A01N037-18
IPCI A01N0037-36 [ICM,7]; A01N0043-00 [ICS,7]; A01N0051-00 [ICS,7];
A01N0037-10 [ICS,7]; A01N0037-18 [ICS,7]
IPCR C07D0261-00 [I,C]; C07D0261-08 [I,A]

PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 5 OF 12 USPATFULL on STN

AN 2001:91602 USPATFULL

TI Crystalline form of 4- [5-methyl-3-phenylisoxazol-4-yl]
benzenesulfonamide

MMP-13 inhibitors

INCL INCLM: 514/378.000
INCLS: 548/240.000
NCL NCLM: 514/378.000
NCLS: 548/247.000; 548/240.000
IC [7]
ICM A61K031-42
IPCI A61K0031-42 [ICM,7]
IPCI-2 A61K0031-42 [ICM,7]; C07D0261-08 [ICS,7]
IPCR C07D0261-00 [I,C]; C07D0261-08 [I,A]

PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 6 OF 12 USPATFULL on STN
AN 2001:4770 USPATFULL
TI Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist
INCL INCLM: 514/395.000
INCLS: 514/406.000; 548/370.100; 548/377.100; 548/364.100; 548/365.700
NCL NCLM: 514/395.000
NCLS: 514/406.000; 548/364.100; 548/365.700; 548/370.100; 548/377.100
IC [7]
ICM A61K031-415
ICS C07D231-02; C07D231-12
IPCI A61K0031-415 [ICM,7]; C07D0231-02 [ICS,7]; C07D0231-12 [ICS,7]
IPCR A61K0038-12 [I,C]; A61K0038-13 [I,A]; A61K0045-00 [I,C];
A61K0045-06 [I,A]

PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 7 OF 12 USPATFULL on STN
AN 1999:146601 USPATFULL
TI Substituted isoxazole for the treatment of inflammation
INCL INCLM: 514/340.000
INCLS: 546/272.100
NCL NCLM: 514/340.000
NCLS: 546/272.100
IC [6]
ICM A61K031-44
ICS C07D413-04; C07D413-06; C07D413-12
IPCI A61K0031-44 [ICM,6]; C07D0413-04 [ICS,6]; C07D0413-06 [ICS,6];
C07D0413-12 [ICS,6]
IPCR C07D0261-00 [I,C]; C07D0261-08 [I,A]; C07D0261-10 [I,A];
C07D0261-12 [I,A]; C07D0261-18 [I,A]; C07D0413-00 [I,C];
C07D0413-04 [I,A]

PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 8 OF 12 USPATFULL on STN
AN 1999:89174 USPATFULL
TI Prodrugs of benzenesulfonamide-containing COX-2 inhibitors
INCL INCLM: 514/341.000
INCLS: 514/374.000; 514/397.000; 514/399.000; 514/403.000; 514/406.000;
514/602.000; 546/274.100; 546/290.000; 548/225.000; 548/228.000;
548/229.000; 548/314.700; 548/315.100; 548/235.000; 548/328.500;
548/335.500; 548/375.100; 548/376.100; 548/377.100; 548/359.500;
548/541.000; 548/544.000; 548/556.000; 564/061.000; 564/084.000
NCL NCLM: 514/341.000
NCLS: 514/374.000; 514/397.000; 514/399.000; 514/403.000; 514/406.000;
514/602.000; 546/274.100; 546/290.000; 548/225.000; 548/228.000;
548/229.000; 548/235.000; 548/314.700; 548/315.100; 548/328.500;
548/335.500; 548/359.500; 548/375.100; 548/376.100; 548/377.100;
548/541.000; 548/544.000; 548/556.000; 564/061.000; 564/084.000
IC [6]
ICM A61K031-42
ICS A61K031-415; A61K031-16; C07D211-72; C07D211-84; C07D263-32;
C07D403-02; C07D223-04; C07D231-10; C07D207-00; C07D207-12

MMP-13 inhibitors

IPCI A61K0031-42 [ICM,6]; A61K0031-415 [ICS,6]; A61K0031-16 [ICS,6];
C07D0211-72 [ICS,6]; C07D0211-84 [ICS,6]; C07D0263-32 [ICS,6];
C07D0403-02 [ICS,6]; C07D0223-04 [ICS,6]; C07D0231-10 [ICS,6];
C07D0207-00 [ICS,6]; C07D0207-12 [ICS,6]
IPCR A61K0031-18 [I,A]; A61K0031-18 [I,C]; A61K0031-415 [I,A];
A61K0031-415 [I,C]; A61K0031-42 [I,A]; A61K0031-42 [I,C];
A61K0031-63 [I,C]; A61K0031-635 [I,A]; C07C0311-00 [I,C];
C07C0311-16 [I,A]; C07C0311-51 [I,A]; C07D0207-00 [I,C];
C07D0207-33 [I,A]; C07D0231-00 [I,C]; C07D0231-12 [I,A];
C07D0233-00 [I,C]; C07D0233-54 [I,A]; C07D0261-00 [I,C];
C07D0261-08 [I,A]; C07D0263-00 [I,C]; C07D0263-32 [I,A];
C07D0307-00 [I,C]; C07D0307-58 [I,A]; C07D0401-00 [I,C];
C07D0401-04 [I,A]; C07D0417-00 [I,C]; C07D0417-04 [I,A];
C07D0495-00 [I,C]; C07D0495-04 [I,A]

PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 9 OF 12 USPATFULL on STN

AN 1999:4908 USPATFULL

TI Isoxazole compounds as cyclooxygenase inhibitors

INCL INCLM: 548/247.000

INCLS: 546/272.100; 548/243.000; 548/245.000; 548/248.000

NCL NCLM: 548/247.000

NCLS: 546/272.100; 548/243.000; 548/245.000; 548/248.000

IC [6]

ICM C07D261-06

IPCI C07D0261-06 [ICM,6]

IPCR C07D0261-00 [I,C]; C07D0261-08 [I,A]; C07D0261-10 [I,A];

C07D0261-12 [I,A]; C07D0261-18 [I,A]; C07D0413-00 [I,C];

C07D0413-04 [I,A]

PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 10 OF 12 USPATFULL on STN

AN 97:120633 USPATFULL

TI Treatment of inflammation and inflammation-related disorders with a
combination of a cyclooxygenase-2 inhibitor and a leukotriene A.sub.4
hydrolase inhibitor

INCL INCLM: 514/326.000

INCLS: 514/330.000; 514/317.000; 514/422.000; 514/445.000; 514/438.000;
514/559.000; 514/602.000; 514/603.000; 514/406.000; 514/407.000;
514/403.000; 514/404.000; 514/567.000; 514/381.000; 514/648.000

NCL NCLM: 514/326.000

NCLS: 514/317.000; 514/330.000; 514/381.000; 514/403.000; 514/404.000;
514/406.000; 514/407.000; 514/422.000; 514/438.000; 514/445.000;
514/559.000; 514/567.000; 514/602.000; 514/603.000; 514/648.000

IC [6]

ICM A61K031-445

ICS A61K031-40; A61K031-38; A61K031-20; A61K031-18; A61K031-415;
A61K031-195; A61K031-135

IPCI A61K0031-445 [ICM,6]; A61K0031-40 [ICS,6]; A61K0031-38 [ICS,6];
A61K0031-20 [ICS,6]; A61K0031-18 [ICS,6]; A61K0031-415 [ICS,6];
A61K0031-195 [ICS,6]; A61K0031-135 [ICS,6]

IPCR A61K0045-00 [I,C]; A61K0045-06 [I,A]

PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 11 OF 12 USPATFULL on STN

AN 97:56699 USPATFULL

TI Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and
5-lipoxygenase inhibitors

INCL INCLM: 514/372.000

INCLS: 514/340.000; 514/369.000; 514/370.000; 514/365.000; 514/376.000;
514/377.000; 514/374.000; 514/378.000; 514/380.000; 546/271.400;
546/272.100; 548/225.000; 548/228.000; 548/229.000; 548/234.000;
548/235.000; 548/236.000; 548/243.000; 548/245.000; 548/246.000;

MMP-13 inhibitors

548/247.000; 548/248.000
 NCL NCLM: 514/372.000
 NCLS: 514/340.000; 514/365.000; 514/369.000; 514/370.000; 514/374.000;
 514/376.000; 514/377.000; 514/378.000; 514/380.000; 546/271.400;
 546/272.100; 548/225.000; 548/228.000; 548/229.000; 548/234.000;
 548/235.000; 548/236.000; 548/243.000; 548/245.000; 548/246.000;
 548/247.000; 548/248.000
 IC [6]
 ICM A61K031-44
 ICS A61K031-425; A61K031-42; C09D263-32; C07D413-12; C07D413-06;
 C07D413-10; C07D417-02
 IPCI A61K0031-44 [ICM,6]; A61K0031-425 [ICS,6]; A61K0031-42 [ICS,6];
 C09D0263-32 [ICS,6]; C07D0413-12 [ICS,6]; C07D0413-06 [ICS,6];
 C07D0413-10 [ICS,6]; C07D0417-02 [ICS,6]
 IPCR C07D0231-00 [I,C]; C07D0231-12 [I,A]; C07D0405-00 [I,C];
 C07D0405-12 [I,A]; C07D0413-00 [I,C]; C07D0413-10 [I,A];
 C07D0413-12 [I,A]

PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

L6 ANSWER 12 OF 12 USPATFULL on STN
 AN 97:45034 USPATFULL
 TI Substituted isoxazoles for the treatment of inflammation
 INCL INCLM: 514/378.000
 INCLS: 548/182.000; 548/186.000; 548/190.000; 548/193.000; 548/202.000;
 548/203.000; 548/225.000; 548/228.000; 548/229.000; 548/232.000;
 548/234.000; 548/235.000; 548/243.000; 548/245.000; 548/247.000;
 548/248.000; 546/272.100; 544/405.000; 514/255.000; 514/340.000;
 514/365.000; 514/369.000; 514/370.000; 514/374.000; 514/376.000;
 514/377.000; 514/380.000
 NCL NCLM: 514/378.000
 NCLS: 514/254.040; 514/340.000; 514/365.000; 514/369.000; 544/405.000;
 546/272.100; 548/182.000; 548/186.000; 548/190.000; 548/193.000;
 548/202.000; 548/203.000; 548/225.000; 548/228.000; 548/229.000;
 548/232.000; 548/234.000; 548/235.000; 548/243.000; 548/245.000;
 548/247.000; 548/248.000
 IC [6]
 ICM C07D261-06
 ICS C07D261-10; C07D261-12; C07D261-14; A61K031-42
 IPCI C07D0261-06 [ICM,6]; C07D0261-10 [ICS,6]; C07D0261-12 [ICS,6];
 C07D0261-14 [ICS,6]; A61K0031-42 [ICS,6]
 IPCR C07D0261-00 [I,C]; C07D0261-08 [I,A]; C07D0261-10 [I,A];
 C07D0261-12 [I,A]; C07D0261-18 [I,A]; C07D0413-00 [I,C];
 C07D0413-04 [I,A]

PAGE IMAGES NOT AVAILABLE FOR THIS PATENT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
4.31	22.00

FULL ESTIMATED COST

STN INTERNATIONAL LOGOFF AT 10:50:35 ON 30 MAR 2006

MMP-13 inhibitors

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 21	IPC search and display fields enhanced in CA/Caplus with the IPC reform
NEWS	4	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2
NEWS	5	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	6	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	7	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	8	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	9	JAN 30	Saved answer limit increased
NEWS	10	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS	11	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	12	FEB 22	Status of current WO (PCT) information on STN
NEWS	13	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	14	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	15	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	16	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	17	FEB 28	TOXCENTER reloaded with enhancements
NEWS	18	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	19	MAR 01	INSPEC reloaded and enhanced
NEWS	20	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	21	MAR 08	X.25 communication option no longer available after June 2006
NEWS	22	MAR 22	EMBASE is now updated on a daily basis

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

MMP-13 inhibitors

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:29:30 ON 30 MAR 2006

=> file caplus uspatfull

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 11:29:50 ON 30 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 11:29:50 ON 30 MAR 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s MMP-13 or (matrix metalloprotease 13)

L1 1801 MMP-13 OR (MATRIX METALLOPROTEASE 13)

=> s L1 and arthritis

L2 898 L1 AND ARTHRITIS

=> dup rem

ENTER L# LIST OR (END):L2

PROCESSING COMPLETED FOR L2

L3 876 DUP REM L2 (22 DUPLICATES REMOVED)

=> s L3 and py<2002

L4 202 L3 AND PY<2002

=> d L4 1-20 ti

L4 ANSWER 1 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Ricin-like toxin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections

L4 ANSWER 2 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Compositions and methods for systemic inhibition of cartilage degradation

L4 ANSWER 3 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors

L4 ANSWER 4 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI IL-1 β -induced expression of matrix metalloproteinases and gliostatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF) in a chondrosarcoma cell line (OUMS-27)

L4 ANSWER 5 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis

L4 ANSWER 6 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Design and synthesis of 4,4-disubstituted piperidine α -sulphone hydroxamates as potent and selective MMP inhibitors: The discovery of SC-77964

L4 ANSWER 7 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Inhibition of tumor necrosis factor- α (TNF- α) production and arthritis in the rat by GW3333, a dual inhibitor of

MMP-13 inhibitors

TNF- α -converting enzyme and matrix metalloproteinases

- L4 ANSWER 8 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI The potential of signal transduction inhibitors for the treatment of arthritis: is it all just JNK?
- L4 ANSWER 9 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Matrix metalloproteinase: Candidate for clinical joint destruction marker in arthropathy
- L4 ANSWER 10 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA
- L4 ANSWER 11 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Tripterygium wilfordii Hook F extract suppresses proinflammatory cytokine-induced expression of matrix metalloproteinase genes in articular chondrocytes by inhibiting activating protein-1 and nuclear factor- κ B activities
- L4 ANSWER 12 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Altered mRNA level of matrix metalloproteinase-13 in MH7A synovial cells under mechanical loading and unloading
- L4 ANSWER 13 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of acetylenic α -amino acid-based sulfonamide hydroxamic acid TACE inhibitors
- L4 ANSWER 14 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Messenger-RNA expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and transcription factors in rheumatic synovial cells under mechanical stimuli
- L4 ANSWER 15 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
- L4 ANSWER 16 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of N-(p-benzyloxybenzenesulfonylamino)piperidine and -piperazine derivatives as selective inhibitors of aggrecanase in osteoarthritis treatment
- L4 ANSWER 17 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Oncostatin m-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires janus kinase/STAT signaling pathway
- L4 ANSWER 18 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl, or heteroaryl amides as matrix metalloproteinase inhibitors
- L4 ANSWER 19 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Interleukin 13 blocks the release of collagen from bovine nasal cartilage treated with proinflammatory cytokines
- L4 ANSWER 20 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI N-Hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroaryl amides as matrix metalloproteinase inhibitors

MMP-13 inhibitors

=> s L4 and allosteric

L5 0 L4 AND ALLOSTERIC

=> s L4 and synthesis

L6 119 L4 AND SYNTHESIS

=> d L4 1-20 ti

L4 ANSWER 1 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Ricin-like toxin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections

L4 ANSWER 2 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Compositions and methods for systemic inhibition of cartilage degradation

L4 ANSWER 3 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors

L4 ANSWER 4 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI IL-1 β -induced expression of matrix metalloproteinases and gliostatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF) in a chondrosarcoma cell line (OUMS-27)

L4 ANSWER 5 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis

L4 ANSWER 6 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Design and synthesis of 4,4-disubstituted piperidine α -sulphone hydroxamates as potent and selective MMP inhibitors: The discovery of SC-77964

L4 ANSWER 7 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Inhibition of tumor necrosis factor- α (TNF- α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF- α -converting enzyme and matrix metalloproteinases

L4 ANSWER 8 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI The potential of signal transduction inhibitors for the treatment of arthritis: is it all just JNK?

L4 ANSWER 9 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Matrix metalloproteinase: Candidate for clinical joint destruction marker in arthropathy

L4 ANSWER 10 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA

L4 ANSWER 11 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Tripterygium wilfordii Hook F extract suppresses proinflammatory cytokine-induced expression of matrix metalloproteinase genes in articular chondrocytes by inhibiting activating protein-1 and nuclear factor- κ B activities

L4 ANSWER 12 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN

TI Altered mRNA level of matrix metalloproteinase-13 in MH7A synovial cells under mechanical loading and unloading

MMP-13 inhibitors

- L4 ANSWER 13 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of acetylenic α -amino acid-based sulfonamide hydroxamic acid TACE inhibitors
- L4 ANSWER 14 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Messenger-RNA expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and transcription factors in rheumatic synovial cells under mechanical stimuli
- L4 ANSWER 15 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
- L4 ANSWER 16 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of N-(p-benzyloxybenzenesulfonylamino)piperidine and -piperazine derivatives as selective inhibitors of aggrecanase in osteoarthritis treatment
- L4 ANSWER 17 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Oncostatin m-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires janus kinase/STAT signaling pathway
- L4 ANSWER 18 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl, or heteroaryl amides as matrix metalloproteinase inhibitors
- L4 ANSWER 19 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI Interleukin 13 blocks the release of collagen from bovine nasal cartilage treated with proinflammatory cytokines
- L4 ANSWER 20 OF 202 CAPLUS COPYRIGHT 2006 ACS on STN
TI N-Hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroaryl amides as matrix metalloproteinase inhibitors

=> s L4 not (tissue(w)inhibitor or TIMP)

L7 150 L4 NOT (TISSUE(W) INHIBITOR OR TIMP)

=> d L7 1-20 ti

- L7 ANSWER 1 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Ricin-like toxin precursors cleavable by disease-specific proteinases for treatment of cancer, viral or parasitic infections
- L7 ANSWER 2 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Compositions and methods for systemic inhibition of cartilage degradation
- L7 ANSWER 3 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
- L7 ANSWER 4 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI IL-1 β -induced expression of matrix metalloproteinases and gliostatin/platelet-derived endothelial cell growth factor (GLS/PD-ECGF) in a chondrosarcoma cell line (OUMS-27)
- L7 ANSWER 5 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Design and synthesis of 4,4-disubstituted piperidine α -sulphone hydroxamates as potent and selective MMP inhibitors: The discovery of SC-77964

MMP-13 inhibitors

- L7 ANSWER 6 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Inhibition of tumor necrosis factor- α (TNF- α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF- α -converting enzyme and matrix metalloproteinases
- L7 ANSWER 7 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI The potential of signal transduction inhibitors for the treatment of arthritis: is it all just JNK?
- L7 ANSWER 8 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Matrix metalloproteinase: Candidate for clinical joint destruction marker in arthropathy
- L7 ANSWER 9 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA
- L7 ANSWER 10 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Tripterygium wilfordii Hook F extract suppresses proinflammatory cytokine-induced expression of matrix metalloproteinase genes in articular chondrocytes by inhibiting activating protein-1 and nuclear factor- κ B activities
- L7 ANSWER 11 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Altered mRNA level of matrix metalloproteinase-13 in MH7A synovial cells under mechanical loading and unloading
- L7 ANSWER 12 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of acetylenic α -amino acid-based sulfonamide hydroxamic acid TACE inhibitors
- L7 ANSWER 13 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
- L7 ANSWER 14 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of N-(p-benzyloxybenzenesulfonylamino)piperidine and -piperazine derivatives as selective inhibitors of aggrecanase in osteoarthritis treatment
- L7 ANSWER 15 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl, or heteroaryl amides as matrix metalloproteinase inhibitors
- L7 ANSWER 16 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI N-Hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroaryl amides as matrix metalloproteinase inhibitors
- L7 ANSWER 17 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Cyclic sulphone MMP inhibitors
- L7 ANSWER 18 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of arylamido-substituted (hetero)cycloalkylacetamides as MMP and TNF- α inhibitors
- L7 ANSWER 19 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors

MMP-13 inhibitors

L7 ANSWER 20 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Preparation of heteroaryl acetylenic sulfonamide and phosphinic acid amide
 hydroxamic acid TACE inhibitors

=> d L7 2-3 ti abs bib .



L7 ANSWER 2 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Compositions and methods for systemic inhibition of cartilage degradation
 AB Methods and compns. for inhibiting articular cartilage degradation are disclosed. The compns. preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compns. may also include one or more pain and inflammation inhibitory agents. The compns. may be administered systemically, such as to treat patients at risk of cartilage degradation at multiple joints, and suitably may be formulated in a carrier or delivery vehicle that is targeted to the joints. Alternatively the compns. may be injected or infused directly into the joint.
 AN 2003:1007594 CAPLUS
 DN 140:47483
 TI Compositions and methods for systemic inhibition of cartilage degradation
 IN Demopoulos, Gregory A.; Palmer, Pamela Pierce; Herz, Jeffrey M.
 PA Omeros Corporation, USA
 SO U.S. Pat. Appl. Publ., 71 pp., Cont.-in-part of U.S. Ser. No. 31,546.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003235589	A1	20031225	US 2003-356649	20030131
	AU 2000011277	A5	20000508	AU 2000-11277	19991020 <--
	EP 1261334	A1	20021204	EP 1999-955097	19991020
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	WO 2000025745	A2	20000511	WO 1999-US26330	19991105 <--
	WO 2000025745	A3	20000824		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	WO 2001007067	A2	20010201	WO 2000-US19864	20000721 <--
	WO 2001007067	A3	20010329		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002028798	A1	20020307	US 2001-839633	20010420
PRAI	US 1998-105026P	P	19981020		
	US 1998-107256P	P	19981105		
	US 1999-144904P	P	19990721		
	WO 1999-US24625	A2	19991020		
	WO 1999-US26330	A2	19991105		

MMP-13 inhibitors

WO 2000-US19864	W	20000721
US 2001-839633	A2	20010420
US 2002-31546	A2	20020118
US 2002-353552P	P	20020201
US 1994-353775	B2	19941212
WO 1995-US16028	A2	19951212
US 1996-670699	A2	19960626
US 1998-72913	A2	19980504
US 1998-105029P	P	19981020
US 1998-105044P	P	19981020
US 1998-105166P	P	19981021
WO 1999-US24557	A2	19991020
WO 1999-US24558	A2	19991020
WO 1999-US24672	A2	19991020

L7 ANSWER 3 OF 150 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Preparation of sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
 GI



AB Title compds. I [W = 6-membered heterocycle containing the sulfonyl bonded N; A-R-E-Y = 4-substituent; A = O, SOO-2, etc.; R = alkyl, alkoxyalkyl, aryl, heteroaryl, cycloalkyl, etc.; E = absent, bond, CO, SO2, etc.; Y = absent, H, OH, CN, NO2, alkyl, haloalkyl, aminoalkyl; R5-6 = together with the atoms to which they are bonded, form an aliphatic or aromatic carbocyclic or

heterocyclic ring having 5-7 members] are prepared Over 50 synthetic examples are disclosed. For example, phthalide is reacted with 4-(phenoxy)benzenethiol (DMF, K2CO3, 100°C, 2 h) and the resulting product converted to the hydroxamic acid (CH2Cl2, ClCOCOC1, DMF (cat), TMSONH2, 0°C, 1.5 h) followed by oxidation (CH2Cl2, mCPBA, room temperature, 3 h) to II. II has IC50 = 10 nM for MMP-2, 45 nM for MMP-13 and >10,000 nM for MMP-1. I are inhibitors of MMP and angiogenesis.

AN 2003:300644 CAPLUS

DN 138:304308

TI Preparation of sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors

MMP-13 inhibitors

IN Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Decrescenzo, Gary A.; Freskos, John N.; Getman, Daniel P.; McDonald, Joseph J.; Mischke, Brent V.; Rao, Shashidhar N.; Villamil, Clara I.
 PA Pharmacia Corp., USA
 SO U.S. Pat. Appl. Publ., 148 pp., Cont.-in-part of U.S. Ser. No. 569,034.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003073845	A1	20030417	US 2001-909227	20010719
	US 6696449	B2	20040224		
	WO 9838859	A1	19980911	WO 1998-US4300	19980304 <--
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 2001020021	A1	20010906	US 1999-230209	19990624 <--
	US 6380258	B2	20020430		
	US 2003191317	A1	20031009	US 2000-728408	20001201
	US 6794511	B2	20040921		
	CA 2453613	AA	20030130	CA 2002-2453613	20020719
	WO 2003007954	A2	20030130	WO 2002-US23219	20020719
	WO 2003007954	A3	20031023		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1406626	A2	20040414	EP 2002-761148	20020719
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002011430	A	20040713	BR 2002-11430	20020719
	JP 2005502632	T2	20050127	JP 2003-513561	20020719
PRAI	US 1997-35182P	P	19970304		
	WO 1998-US4300	W	19980304		
	US 1999-310813	B1	19990512		
	US 1999-310813	B2	19990512		
	US 1999-230209	A2	19990624		
	US 2000-569034	A2	20000511		
	US 2000-728408	A2	20001201		
	US 2001-909227	A	20010719		
	WO 2002-US23219	W	20020719		
OS	MARPAT 138:304308				

=> file uspatfull
 COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE
 ENTRY
 57.67

TOTAL
 SESSION
 57.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE
 ENTRY
 -1.50

TOTAL
 SESSION
 -1.50

MMP-13 inhibitors

FILE 'USPATFULL' ENTERED AT 11:35:20 ON 30 MAR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 30 Mar 2006 (20060330/PD)
FILE LAST UPDATED: 30 Mar 2006 (20060330/ED)
HIGHEST GRANTED PATENT NUMBER: US7020895
HIGHEST APPLICATION PUBLICATION NUMBER: US2006070159
CA INDEXING IS CURRENT THROUGH 28 Mar 2006 (20060328/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 30 Mar 2006 (20060330/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006

```
=> s MMP-13 or (matrix metalloprotease 13)
      4748 MMP
      3249028 13
        797 MMP-13
          (MMP(W)13)
      402597 MATRIX
        2958 METALLOPROTEASE
      3249028 13
        28 MATRIX METALLOPROTEASE 13
          (MATRIX(W)METALLOPROTEASE(W)13)
L8      798 MMP-13 OR (MATRIX METALLOPROTEASE 13)
```

```
=> s L8 and arthritis and py<2002
      47782 ARTHRITIS
      3023199 PY<2002
L9      136 L8 AND ARTHRITIS AND PY<2002
```

```
=> s L9 not (tissue(w)inhibitor or TIMP)
      278935 TISSUE
      137772 INHIBITOR
        2154 TISSUE(W)INHIBITOR
        2226 TIMP
L10      94 L9 NOT (TISSUE(W)INHIBITOR OR TIMP)
```

```
=> d L10 1-20 free
'FREE' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'
```

The following are valid formats:

The default display format is STD.

```
ABS ----- AB
ALL ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,
            RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,
            DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,
            INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI,
            IPCI-2, IPCR, EXF, ARTU
ALLG ----- ALL plus PAGE.DRAW
BIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,
            PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT
BIB.EX ----- BIB for original and latest publication
BIBG ----- BIB plus PAGE.DRAW
BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE". BROWSE must
               entered on the same line as DISPLAY, e.g., D BROWSE.
CAS ----- OS, CC, SX, ST, IT
CBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS
DALL ----- ALL, delimited for post-processing
FP ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,
           PRAI, IC, IPCI, IPCI-2, IPCR, INCL, INCLM, INCLS, NCL,
```

MMP-13 inhibitors

NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP, CLMN, DRWN, AB

FP.EX ----- FP for original and latest publication

FPALL ----- PI, TI, IN, INA, PA, PAA, PAT, PETRM, DCD, AI, RLI, PRAI, IC, IPCI, IPCI-2, IPCR, INCL, INCLM, INCLS, NCL, NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP, CLMN, DRWN, AB, PARN, SUMM, DRWD, DETD, CLM

FPBIB ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN

FHITSTR ---- HIT RN, its text modification, its CA index name, and its structure diagram

FPG ----- FP plus PAGE.DRAW

GI ----- PN and page image numbers

HIT ----- All fields containing hit terms

HITRN ----- HIT RN and its text modification

HITSTR ----- HIT RN, its text modification, its CA index name, and its structure diagram

IABS ----- ABS, indented with text labels

IALL ----- ALL, indented with text labels

IALLG ----- IALL plus PAGE.DRAW

IBIB ----- BIB, indented with text labels

IBIB.EX ---- IBIB for original and latest publication

IBIBG ----- IBIB plus PAGE.DRAW

IMAX ----- MAX, indented with text labels

IMAX.EX ---- IMAX for original and latest publication

IND ----- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR, EXF, ARTU, OS, CC, SX, ST, IT

IPC.TAB ---- IPC in tabular format

ISTD ----- STD, indented with text labels

KWIC ----- All hit terms plus 20 words on either side

MAX ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL, DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR, EXF, ARTU OS, CC, SX, ST, IT

MAX.EX ---- MAX for original and latest publication

OCC ----- List of display fields containing hit terms

SBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI, DT, FS, LN.CNT

STD ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI, DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR, EXF (STD is the default)

STD.EX ---- STD for original and latest publication

TRIAL ----- AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR

SCAN ----- AN, TI, NCL, NCLM, NCLS, IC, IPCI, IPCI-2, IPCR (random display without answer number. SCAN must be entered on the same line as DISPLAY, e.g., D SCAN)

ENTER DISPLAY FORMAT (STD):ti

L10 ANSWER 1 OF 94 USPATFULL on STN

TI Benzimidazole derivatives useful as antiproliferative agents

L10 ANSWER 2 OF 94 USPATFULL on STN

TI Use of immunosuppressants for MMP mediated diseases

L10 ANSWER 3 OF 94 USPATFULL on STN

TI 3-Arylsulfonyl-2 (substituted methyl) propanoic acid derivatives as matrix metalloproteinase inhibitors

L10 ANSWER 4 OF 94 USPATFULL on STN

TI Phosphinic pseudo-peptides that may be used as matrix zinc

MMP-13 inhibitors

metalloprotease inhibitors

- L10 ANSWER 5 OF 94 USPATFULL on STN
TI 2,3-substituted indole compounds as anti-inflammatory and analgesic agents
- L10 ANSWER 6 OF 94 USPATFULL on STN
TI Carboxylic and hydroxamic acid compounds inhibiting metalloproteases, method for preparing same and pharmaceutical compositions containing them
- L10 ANSWER 7 OF 94 USPATFULL on STN
TI Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
- L10 ANSWER 8 OF 94 USPATFULL on STN
TI N-hydroxacylamino compounds, process for their preparation and pharmaceutical compositions containing them
- L10 ANSWER 9 OF 94 USPATFULL on STN
TI Aromatic sulfone hydroxamic acid metalloprotease inhibitor
- L10 ANSWER 10 OF 94 USPATFULL on STN
TI Hydroxamic acid derivatives as matrix metalloprotease (MMP) inhibitors
- L10 ANSWER 11 OF 94 USPATFULL on STN
TI Hydroxamic acid derivatives as proteinase inhibitors
- L10 ANSWER 12 OF 94 USPATFULL on STN
TI Thiol compounds, their production and use
- L10 ANSWER 13 OF 94 USPATFULL on STN
TI Hydroxamic acid derivatives as matrix metalloprotease (MMP) inhibitors
- L10 ANSWER 14 OF 94 USPATFULL on STN
TI Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
- L10 ANSWER 15 OF 94 USPATFULL on STN
TI Piperazine compounds as inhibitors of MMP or TNF
- L10 ANSWER 16 OF 94 USPATFULL on STN
TI N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl, Sulfanyl, Sulfinyl or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase inhibitors
- L10 ANSWER 17 OF 94 USPATFULL on STN
TI Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
- L10 ANSWER 18 OF 94 USPATFULL on STN
TI Formamide compounds as therapeutic agents
- L10 ANSWER 19 OF 94 USPATFULL on STN
TI Hydroxy pipercolate hydroxamic acid derivatives
- L10 ANSWER 20 OF 94 USPATFULL on STN
TI Acetylenic β -sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors

=> d L10 3 5 15-17 ti bib

MMP-13 inhibitors

L10 ANSWER 3 OF 94 USPATFULL on STN

TI 3-Arylsulfonyl-2 (substituted methyl) propanoic acid derivatives as matrix metalloproteinase inhibitors

AN 2004:181063 USPATFULL

TI 3-Arylsulfonyl-2 (substituted methyl) propanoic acid derivatives as matrix metalloproteinase inhibitors

IN Mantegani, Sergio, Milan, ITALY

Abrate, Francesca, Milan, ITALY

Bissolino, Pierluigi, Pavia, ITALY

Cremonesi, Paolo, Milan, ITALY

Perrone, Ettore, Milan, ITALY

Jabes, Daniela, Milan, ITALY

PA Pharmacia Italia, SpA, Milan, ITALY (non-U.S. corporation)

PI US 6765003 B1 20040720

WO 2001005756 20010125

<--

AI US 2002-30681 20020409 (10)

WO 2000-EP6429 20000707

PRAI GB 1999-16562 19990714

DT Utility

FS GRANTED

EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Patel, Sudhaker B.

LREP Akin Gump Strauss Hauer & Feld LLP, Mason, Dwayne L.

CLMN Number of Claims: 13

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 1787

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 94 USPATFULL on STN

TI 2,3-substituted indole compounds as anti-inflammatory and analgesic agents

AN 2003:222110 USPATFULL

TI 2,3-substituted indole compounds as anti-inflammatory and analgesic agents

IN Nakao, Kazunari, 29-1, Sinbayashi, Shinbayahi-cho, Chiryu-shi,

Aichi-ken, JAPAN 472-0017

Stevens, Rodney William, 3-4-26, Seoshiro-cho, Handa-shi, Aichi-ken, JAPAN 484-0081

Kawamura, Kiyoshi, 40-1, Daimonsaki, Inuyama, Inuyama-shi, Aichi-ken, JAPAN 484-0081

Uchida, Chikara, 118-401, Miyaji-cho, Handa-shi, Aichi-ken, JAPAN 475-0902

Koike, Hiroki, 1-100 Souga-cho, Handa-shi, Aichi-ken, JAPAN 475-0801

Caron, Stephane, 600 Meridian St. Extension-Apt. 509, Groton, CT, United States 06340

PI US 6608070 B1 20030819

WO 9935130 19990715

<--

AI US 1999-355494 19990728 (9)

WO 1998-IB2065 19981218

DT Utility

FS GRANTED

EXNAM Primary Examiner: Seaman, D. Margaret

LREP Richardson, Peter C., Ginsburg, Paul H., Catania, Richard L.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 10227

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 15 OF 94 USPATFULL on STN

TI Piperazine compounds as inhibitors of MMP or TNF

AN 2001:235249 USPATFULL

MMP-13 inhibitors

TI Piperazine compounds as inhibitors of MMP or TNF
 IN Neya, Masahiro, Tsuchiura, Japan
 Yamazaki, Hitoshi, Tsukuba, Japan
 Kayakiri, Natsuko, Suita, Japan
 Sato, Kentaro, Tsukuba, Japan
 Oku, Teruo, Takatsuki, Japan
 PA Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)
 PI US 6333324 B1 20011225 <--
 WO 9827069 19980625 <--
 AI US 1999-319928 19990726 (9)
 WO 1997-JP4613 19971215
 19990726 PCT 371 date
 19990726 PCT 102(e) date
 PRAI AU 1996-4249 19961217
 AU 1997-7156 19970603
 AU 1997-8568 19970814
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Liu, Hong
 LREP Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
 CLMN Number of Claims: 9
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 5901
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 16 OF 94 USPATFULL on STN

TI N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl, Sulfanyl, Sulfinyl or
 Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix
 Metalloproteinase inhibitors
 AN 2001:231300 USPATFULL
 TI N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl, Sulfanyl, Sulfinyl or
 Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix
 Metalloproteinase inhibitors
 IN Venkatesan, Aranapakam Mudumbai, 97-07 63rd Rd., #9K, Rego Park, NY,
 United States 11374
 Grosu, George Theodore, 117 Prospect Pl., Pearl River, NY, United States
 10965
 Baker, Jannie Lea, 127 Rockinchair Rd., White Plains, NY, United States
 10607
 PI US 6331563 B1 20011218 <--
 AI US 2000-587560 20000605 (9)
 RLI Division of Ser. No. US 1998-140504, filed on 26 Aug 1998, now patented,
 Pat. No. US 6197791 Continuation-in-part of Ser. No. US 1998-26372,
 filed on 19 Feb 1998, now abandoned
 PRAI US 1997-38899P 19970227 (60)
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Aulakh, Charanjit S.
 LREP Hogan, Jr., John W.
 CLMN Number of Claims: 9
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 6776
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 17 OF 94 USPATFULL on STN

TI Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as
 matrix metalloproteinase and TACE inhibitors
 AN 2001:229661 USPATFULL
 TI Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as
 matrix metalloproteinase and TACE inhibitors
 IN Levin, Jeremy Ian, Nanuet, NY, United States

MMP-13 inhibitors

Nelson, Frances Christy, Wyckoff, NJ, United States
PI US 2001051614 A1 20011213 <--
AI US 2000-725707 A1 20001129 (9)
RLI Continuation of Ser. No. US 1999-330717, filed on 11 Jun 1999, GRANTED,
Pat. No. US 6197795 Division of Ser. No. US 1997-944400, filed on 6 Oct
1997, GRANTED, Pat. No. US 5962481
PRAI US 1996-28969P 19961016 (60)
DT Utility
FS APPLICATION
LREP AMERICAN HOME PRODUCTS CORPORATION, PATENT SECTION, FIVE GIRALDA FARMS,
MADISON, NJ, 07940-0874
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1089
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d L10 21-40 ti

L10 ANSWER 21 OF 94 USPATFULL on STN
TI Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic
acids as matrix metalloproteinase and TACE inhibitors

L10 ANSWER 22 OF 94 USPATFULL on STN
TI 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit
matrix metalloproteinases

L10 ANSWER 23 OF 94 USPATFULL on STN
TI AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR

L10 ANSWER 24 OF 94 USPATFULL on STN
TI Acetylenic sulfonamide thiol tace inhibitors

L10 ANSWER 25 OF 94 USPATFULL on STN
TI Metalloproteinase inhibitors, pharmaceutical compositions containing
them, and their use

L10 ANSWER 26 OF 94 USPATFULL on STN
TI Arylsulfonylamino hydroxamic acid derivatives

L10 ANSWER 27 OF 94 USPATFULL on STN
TI Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents

L10 ANSWER 28 OF 94 USPATFULL on STN
TI Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic
acids as matrix metalloproteinase and tace inhibitors

L10 ANSWER 29 OF 94 USPATFULL on STN
TI Sulfonylbenzene compounds as anti-inflammatory/analgesic agents

L10 ANSWER 30 OF 94 USPATFULL on STN
TI Heterocyclic hydroxamic acid derivatives as MMP inhibitors

L10 ANSWER 31 OF 94 USPATFULL on STN
TI Procollagen C-proteinase inhibitors

L10 ANSWER 32 OF 94 USPATFULL on STN
TI N-hydroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or
sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix
metalloproteinase inhibitors

L10 ANSWER 33 OF 94 USPATFULL on STN

MMP-13 inhibitors

TI Diagnostic method for detection of periodontitis or peri-implantitis

L10 ANSWER 34 OF 94 USPATFULL on STN

TI Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid
TACE inhibitors

L10 ANSWER 35 OF 94 USPATFULL on STN

TI Substituted indole compounds as anti-inflammatory and analgesic agents

L10 ANSWER 36 OF 94 USPATFULL on STN

TI AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR

L10 ANSWER 37 OF 94 USPATFULL on STN

TI Process for preparing phenoxyphenylsulfonyl halides

L10 ANSWER 38 OF 94 USPATFULL on STN

TI Aryloxy-alkyl-dialkylamines

L10 ANSWER 39 OF 94 USPATFULL on STN

TI Human neutrophil collagenase splice variant

L10 ANSWER 40 OF 94 USPATFULL on STN

TI Aryloxy-alkyl-dialkylamines

=> d L10 21-40 ti bib

L10 ANSWER 21 OF 94 USPATFULL on STN

TI Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic
acids as matrix metalloproteinase and TACE inhibitors

AN 2001:218499 USPATFULL

TI Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic
acids as matrix metalloproteinase and TACE inhibitors

IN Levin, Jeremy I., Nanuet, NY, United States
Zask, Arie, New York, NY, United States
Gu, Yansong, Pearl River, NY, United States
Albright, Jay D., Nanuet, NY, United States
Du, Xuemei, Valley Cottage, NY, United States

PI US 2001046989 A1 20011129 <--

US 6548524 B2 20030415

AI US 2000-734140 A1 20001211 (9)

RLI Continuation-in-part of Ser. No. US 1997-944188, filed on 6 Oct 1997,
ABANDONED

PRAI US 1996-28505P 19961016 (60)

DT Utility

FS APPLICATION

LREP BARRETT, REBECCA RALPH, WYETH AYERST, P.O. BOX 8299, PHILADELPHIA, PA,
19101

CLMN Number of Claims: 12

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2535

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 22 OF 94 USPATFULL on STN

TI 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit
matrix metalloproteinases

AN 2001:205917 USPATFULL

TI 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit
matrix metalloproteinases

IN Robinson, Ralph P., Gales Ferry, CT, United States
Laird, Ellen R., Mystic, CT, United States

PI US 2001041710 A1 20011115 <--

MMP-13 inhibitors

US 6458822 B2 20021001
AI US 2000-730302 A1 20001205 (9)
PRAI US 2000-188892P 20000313 (60)
DT Utility
FS APPLICATION
LREP Paul H. Ginsburg, Pfizer Inc, 20th Floor, 235 East 42nd Street, New York, NY, 10017-5755
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 23 OF 94 USPATFULL on STN
TI AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR
AN 2001:200180 USPATFULL
TI AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR
IN BARTA, THOMAS E, EVANSTON, IL, United States
BECKER, DANIEL P, GLENVIEW, IL, United States
BOEHM, TERRI L, BALLWIN, MO, United States
DECRESCENZO, GARY A, ST CHARLES, MO, United States
WILLAMI1, CLARA I, GLENVIEW, IL, United States
MCDONALD, JOSEPH J, BALLWIN, MO, United States
FRESKOS, JOHN N, CLAYTON, MO, United States
GETMAN, DANIEL P, CHESTERFIELD, MO, United States
HANSON, GUNNAR J, SKOKIE, IL, United States

PI US 2001039287 A1 20011108 <--
AI US 1999-256948 A1 19990224 (9)
PRAI US 1997-66007P 19971114 (60)
US 1998-95347P 19980804 (60)
US 1998-95501P 19980806 (60)
US 1998-101080P 19980918 (60)
DT Utility
FS APPLICATION
LREP WELSH & KATZ, 120 SOUTH RIVERSIDE PLAZA, 22ND FLOOR, CHICAGO, IL, 606063913
CLMN Number of Claims: 146
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 16461
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 24 OF 94 USPATFULL on STN
TI Acetylenic sulfonamide thiol tace inhibitors
AN 2001:197020 USPATFULL
TI Acetylenic sulfonamide thiol tace inhibitors
IN Levin, Jeremy I., New City, NY, United States
Chen, James M., Stoddard Court, NJ, United States
PA American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
PI US 6313123 B1 20011106 <--
AI US 2000-492974 20000127 (9)
PRAI US 1999-155218P 19990127 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Ramsuer, Robert W.
LREP Hogan, Jr., John W.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1035
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 25 OF 94 USPATFULL on STN

MMP-13 inhibitors

TI Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
 AN 2001:185326 USPATFULL
 TI Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
 IN Bender, Steven L., Oceanside, CA, United States
 Castelhana, Arlindo L., New City, NY, United States
 Chong, Wesley K. M., Encinitas, CA, United States
 Abreo, Melwyn A., Imperial Beach, CA, United States
 Billedeau, Roland J., Santa Clara, CA, United States
 Chen, Jian Jeffrey, Santa Clara, CA, United States
 Deal, Judith G., Temecula, CA, United States
 PA Agouron Pharmaceuticals, Inc., La Jolla, CA, United States (U.S. corporation)
 Syntex Inc., Palo Alto, CA, United States (U.S. corporation)
 PI US 6306892 B1 20011023 <--
 AI US 2000-598208 20000621 (9)
 RLI Division of Ser. No. US 1999-309602, filed on 11 May 1999, now patented, Pat. No. US 6174915 Division of Ser. No. US 1997-823962, filed on 25 Mar 1997, now patented, Pat. No. US 6008243
 PRAI US 1996-29115P 19961024 (60)
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Aulakh, Charanjit S.
 CLMN Number of Claims: 20
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 6478
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 26 OF 94 USPATFULL on STN
 TI Arylsulfonylamino hydroxamic acid derivatives
 AN 2001:179128 USPATFULL
 TI Arylsulfonylamino hydroxamic acid derivatives
 IN Robinson, Jr., Ralph Pelton, Gales Ferry, CT, United States
 McClure, Kim Francis, Mystic, CT, United States
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)
 PI US 6303636 B1 20011016 <--
 WO 9833768 19980806 <--
 AI US 1999-355163 19990722 (9)
 WO 1998-IB23 19980112
 19990722 PCT 371 date
 19990722 PCT 102(e) date
 PRAI US 1997-36857P 19970203 (60)
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Chang, Ceila
 LREP Richardson, Peter C., Ginsburg, Paul H., Butterfield, Garth
 CLMN Number of Claims: 8
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 980
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 27 OF 94 USPATFULL on STN
 TI Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents
 AN 2001:179120 USPATFULL
 TI Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents
 IN Nakao, Kazunari, Chita-Gun, Japan
 Hayashi, Shigeo, Chita-Gun, Japan
 Stevens, Rodney W., Chita-Gun, Japan
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)
 PI US 6303628 B1 20011016 <--

MMP-13 inhibitors

AI US 2000-605811 20000628 (9)
 RLI Continuation of Ser. No. WO 1999-IB1243, filed on 2 Jul 1999
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Davis, Zinna Northington
 LREP Richardson, Peter C., Ginsburg, Paul H., Djuardi, Elsa
 CLMN Number of Claims: 12
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1846

L10 ANSWER 28 OF 94 USPATFULL on STN

TI Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
 AN 2001:165837 USPATFULL
 TI Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
 IN Levin, Jeremy I., Nanuet, NY, United States
 Zask, Arie, New York, NY, United States
 Gu, Yansong, Pearl River, NY, United States
 Albright, Jay D., Nanuet, NY, United States
 Du, Xuemei, Valley Cottage, NY, United States
 PI US 2001025047 A1 20010927 <--
 US 6498167 B2 20021224
 AI US 2000-734056 A1 20001211 (9)
 RLI Division of Ser. No. US 1998-59554, filed on 14 Apr 1998, GRANTED, Pat. No. US 6228869 Continuation-in-part of Ser. No. US 1998-55856, filed on 6 Apr 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-944188, filed on 6 Oct 1997, ABANDONED
 PRAI US 1996-28505P 19961016 (60)
 DT Utility
 FS APPLICATION
 LREP Ronald W. Alice, American Home Products Corporation, Patent Law Department - 2B, One Campus Drive, Parsippany, NJ, 07054
 CLMN Number of Claims: 12
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2510
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 29 OF 94 USPATFULL on STN

TI Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
 AN 2001:163224 USPATFULL
 TI Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
 IN Ando, Kazuo, Chita-gun, Japan
 Kato, Tomoki, Chita-gun, Japan
 Kawai, Akiyoshi, Chita-gun, Japan
 Nonomura, Tomomi, Chita-gun, Japan
 PA Pfizer Inc., New York, NY, United States (U.S. corporation)
 PI US 6294558 B1 20010925 <--
 WO 9711704 19970403 <--
 AI US 1999-446049 19991215 (9)
 WO 1999-IB970 19990531
 19991215 PCT 371 date
 19991215 PCT 102(e) date
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Patel, Sudhaker B.
 LREP Richardson, Peter C., Ginsburg, Paul H., Looney, Adrian G.
 CLMN Number of Claims: 30
 ECL Exemplary Claim: 1
 DRWN No Drawings

MMP-13 inhibitors

LN.CNT 8683

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 30 OF 94 USPATFULL on STN

TI Heterocyclic hydroxamic acid derivatives as MMP inhibitors
AN 2001:163207 USPATFULL
TI Heterocyclic hydroxamic acid derivatives as MMP inhibitors
IN Lou, Boliang, Louisville, KY, United States
Mjalli, Adnan M. M., Jamestown, NC, United States
PA Advanced Syntech, LLC, Louisville, KY, United States (U.S. corporation)
PI US 6294539 B1 20010925 <--
AI US 2000-487528 20000119 (9)
PRAI US 1999-116250P 19990119 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Patel, Sudhaker B.
LREP Vanderburgh, John E.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 1015

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 31 OF 94 USPATFULL on STN

TI Procollagen C-proteinase inhibitors
AN 2001:155784 USPATFULL
TI Procollagen C-proteinase inhibitors
IN Bailey, Simon, County of Kent, Great Britain
Billotte, Stephane, County of Kent, Great Britain
Derrick, Andrew Michael, County of Kent, Great Britain
Fish, Paul Vincent, County of Kent, Great Britain
James, Kim, County of James, Great Britain
Thomson, Nicholas Murray, County of Kent, Great Britain
PI US 2001021718 A1 20010913 <--
US 6448278 B2 20020910
AI US 2000-735968 A1 20001213 (9)
PRAI GB 1999-30570 19991223
US 2000-180527P 20000207 (60)
DT Utility
FS APPLICATION
LREP Paul H. Ginsburg, Pfizer Inc, 235 East 42nd Street, 20th Floor, New York, NY, 10017-5755
CLMN Number of Claims: 53
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 5478

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 32 OF 94 USPATFULL on STN

TI N-hydroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
AN 2001:152983 USPATFULL
TI N-hydroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
IN Venkatesan, Aranapakam Mudumbai, Rego Park, NY, United States
PA American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
PI US 6288086 B1 20010911 <--
AI US 2000-593918 20000614 (9)
RLI Division of Ser. No. US 1998-140504, filed on 26 Aug 1998, now patented, Pat. No. US 6197791 Continuation-in-part of Ser. No. US 1998-26372,

MMP-13 inhibitors

filed on 19 Feb 1998, now abandoned
PRAI US 1997-38899P 19970227 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Aulakh, Charanjit
LREP Hogan, Jr., John W.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 6559
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 33 OF 94 USPATFULL on STN
TI Diagnostic method for detection of periodontitis or peri-implantitis
AN 2001:141837 USPATFULL
TI Diagnostic method for detection of periodontitis or peri-implantitis
IN Golub, Lorne M., Smithtown, NY, United States
Sorsa, Timo, Helsinki, Finland
Teronen, Olli, Helsinki, Finland
Tikanoja, Sari Hannele, Helsinki, Finland
PA The Research Foundation of State University of NY, Albany, NY, United States (U.S. corporation)
Medix Biochemica, Kauniainen, Finland (non-U.S. corporation)
PI US 6280687 B1 20010828 <--
AI US 2000-642380 20000821 (9)
RLI Division of Ser. No. US 1998-133887, filed on 13 Aug 1998, now patented, Pat. No. US 6143506
DT Utility
FS GRANTED
EXNAM Primary Examiner: Stucker, Jeffrey
LREP Hoffmann & Baron, LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 8 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 1767
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 34 OF 94 USPATFULL on STN
TI Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
AN 2001:136688 USPATFULL
TI Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
IN Levin, Jeremy I., New City, NY, United States
Chen, James M., Stoddard Court, NJ, United States
PA American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
PI US 6277885 B1 20010821 <--
AI US 2000-491636 20000127 (9)
PRAI US 1999-155204P 19990127 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Raymond, Richard L.
LREP Hogan, Jr., John W.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2073
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 35 OF 94 USPATFULL on STN
TI Substituted indole compounds as anti-inflammatory and analgesic agents
AN 2001:136681 USPATFULL
TI Substituted indole compounds as anti-inflammatory and analgesic agents

MMP-13 inhibitors

IN Nakao, Kazunari, Chita-gun, Japan
 Stevens, Rodney W., Chita-gun, Japan
 Kawamura, Kiyoshi, Chita-gun, Japan
 Uchida, Chikara, Chita-gun, Japan
 PA Pfizer Inc, New York, NY, United States (U.S. corporation)
 PI US 6277878 B1 20010821 <--
 AI US 1999-383353 19990826 (9)
 PRAI WO 1998-IB1382 19980907
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Raymond, Richard L.; Assistant Examiner: Liu, Hong
 LREP Richardson, Peter C., Ginsburg, Paul H., Djuardi, Elsa
 CLMN Number of Claims: 11
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2629
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 36 OF 94 USPATFULL on STN
 TI AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR
 AN 2001:134239 USPATFULL
 TI AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR
 IN BARTA, THOMAS E., EVANSTON, IL, United States
 BECKER, DANIEL P., GLENVIEW, IL, United States
 BOEHM, TERRI L., BALLWIN, MO, United States
 DECRESCENZO, GARY A., ST.CHARLES, MO, United States
 WILLAMIL, CLARA I., GLENVIEW, IL, United States
 MCDONALD, JOSEPH J., BALLWIN, MO, United States
 FRESKOS, JOHN N., CLAYTON, MO, United States
 GETMAN, DANIEL P., CHESTERFIELD, MO, United States
 HANSON, GUNNAR J., STOKIE, IL, United States
 PI US 2001014688 A1 20010816 <--
 AI US 1998-191129 A1 19981113 (9)
 PRAI US 1997-66007P 19971114 (60)
 US 1998-95347P 19980804 (60)
 US 1998-95501P 19980806 (60)
 DT Utility
 FS APPLICATION
 LREP WELSH AND KATZ, 120 SOUTH RIVERSIDE PLAZA, 22ND FLOOR, CHICAGO, IL,
 606063913
 CLMN Number of Claims: 142
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 15774
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 37 OF 94 USPATFULL on STN
 TI Process for preparing phenoxyphenylsulfonyl halides
 AN 2001:123634 USPATFULL
 TI Process for preparing phenoxyphenylsulfonyl halides
 IN Hawkins, Joel M., Old Lyme, CT, United States
 PI US 2001011143 A1 20010802 <--
 AI US 2000-740398 A1 20001219 (9)
 RLI Continuation of Ser. No. US 2000-503460, filed on 14 Feb 2000, PENDING
 Continuation of Ser. No. US 1999-287930, filed on 7 Apr 1999, GRANTED,
 Pat. No. US 6118016
 PRAI US 1998-81393P 19980410 (60)
 DT Utility
 FS APPLICATION
 LREP Paul H. Ginsburg, Esq., Pfizer Inc, Patent Dept., 20th Floor, 235 East
 42nd Street, New York, NY, 10017-5755
 CLMN Number of Claims: 15
 ECL Exemplary Claim: 1

MMP-13 inhibitors

DRWN No Drawings

LN.CNT 646

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 38 OF 94 USPATFULL on STN

TI Aryloxy-alkyl-dialkylamines

AN 2001:121611 USPATFULL

TI Aryloxy-alkyl-dialkylamines

IN Raveendranath, Panolil, Monroe, NY, United States

Zeldis, Joseph, New City, NY, United States

Vid, Galina, New City, NY, United States

Potoski, John R., West Nyack, NY, United States

Ren, Jianxin, Tenafly, NJ, United States

Iera, Silvio, Montreal, Canada

PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)

PI US 6268504 B1 20010731 <--

AI US 1999-458317 19991210 (9)

RLI Division of Ser. No. US 1998-161653, filed on 28 Sep 1998, now patented, Pat. No. US 6005102

DT Utility

FS GRANTED

EXNAM Primary Examiner: Higel, Floyd D.; Assistant Examiner: Sackey, Ebenezer

LREP Eck, Steven R.

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1710

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 39 OF 94 USPATFULL on STN

TI Human neutrophil collagenase splice variant

AN 2001:100857 USPATFULL

TI Human neutrophil collagenase splice variant

IN Hu, Shou-Ih, New Providence, NJ, United States

PA Novartis AG, Basel, Switzerland (non-U.S. corporation)

PI US 1973 H1 20010703 <--

AI US 1998-178002 19981022 (9)

DT Statutory

FS GRANTED

EXNAM Primary Examiner: Carone, Michael J.; Assistant Examiner: Baker, Aileen J.

LREP Ferraro, Gregory D.

CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN 5 Drawing Figure(s); 3 Drawing Page(s)

LN.CNT 1628

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 40 OF 94 USPATFULL on STN

TI Aryloxy-alkyl-dialkylamines

AN 2001:82930 USPATFULL

TI Aryloxy-alkyl-dialkylamines

IN Raveendranath, Panolil, Monroe, NY, United States

Zeldis, Joseph, New City, NY, United States

Vid, Galina, New City, NY, United States

Potoski, John R., West Nyack, NY, United States

Ren, Jianxin, Tenafly, NJ, United States

Iera, Silvio, Montreal, Canada

PA American Home Products Corporation, Madison, NJ, United States (U.S. corporation)

PI US 6242605 B1 20010605 <--

AI US 1999-458316 19991210 (9)

MMP-13 inhibitors

RLI Division of Ser. No. US 1998-161653, filed on 28 Sep 1998, now patented,
Pat. No. US 6005102
PRAI US 1997-90099P 19971015 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Higel, Floyd D.; Assistant Examiner: Sackey, Ebenezer
LREP Eck, Steven R.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1715
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	35.01	92.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.50

STN INTERNATIONAL LOGOFF AT 11:39:32 ON 30 MAR 2006

MMP-13 inhibitors

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 21	IPC search and display fields enhanced in CA/CAPLUS with the IPC reform
NEWS	4	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2
NEWS	5	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	6	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	7	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	8	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	9	JAN 30	Saved answer limit increased
NEWS	10	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA
NEWS	11	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	12	FEB 22	Status of current WO (PCT) information on STN
NEWS	13	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	14	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	15	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	16	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	17	FEB 28	TOXCENTER reloaded with enhancements
NEWS	18	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	19	MAR 01	INSPEC reloaded and enhanced
NEWS	20	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	21	MAR 08	X.25 communication option no longer available after June 2006
NEWS	22	MAR 22	EMBASE is now updated on a daily basis
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

MMP-13 inhibitors

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:40:17 ON 30 MAR 2006

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CAPLUS' ENTERED AT 12:41:02 ON 30 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Mar 2006 VOL 144 ISS 14

FILE LAST UPDATED: 29 Mar 2006 (20060329/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s MMP-13(inhibitor)

MISSING OPERATOR 'MMP-13(INHIBITOR'

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s MMP-13(w)inhibitor

13340 MMP

813714 13

982 MMP-13

(MMP(W) 13)

501944 INHIBITOR

L1 21 MMP-13 (W) INHIBITOR

=> s L1 and py<2002

21808396 PY<2002

L2 4 L1 AND PY<2002

=> d 1-4 ti

L2 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P11 groups

L2 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design

L2 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials

MMP-13 inhibitors

L2 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN


TI synthesis and identification of conformationally constrained selective MMP inhibitors

=> d 1-4 ti abs bib

L2 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P11 groups

GI



I

AB A novel series of anthranilic acid-based inhibitors of MMP-1, MMP-9, MMP-13, and TACE was prepared and evaluated. Selective inhibitors of MMP-9, MMP-13, and TACE were identified, including the potent, orally active **MMP-13 inhibitor I**.

AN 2001:612039 CAPLUS

DN 136:163

TI The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P11 groups

AU Levin, J. I.; Chen, J.; Du, M.; Hogan, M.; Kincaid, S.; Nelson, F. C.; Venkatesan, A. M.; Wehr, T.; Zask, A.; DiJoseph, J.; Killar, L. M.; Skala, S.; Sung, A.; Sharr, M.; Roth, C.; Jin, G.; Cowling, R.; Mohler, K. M.; Black, R. A.; March, C. J.; Skotnicki, J. S.

CS Wyeth-Ayerst Research, Pearl River, NY, 10965, USA

SO Bioorganic & Medicinal Chemistry Letters (2001), 11(16), 2189-2192

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design

AB The high-resolution NMR solution structure of the catalytic fragment of human collagenase-3 (MMP-13) was used as a starting point for structure-based design of selective inhibitors for MMP-13. The major structural difference observed between the MMP structures is the relative size and shape of the S1' pocket where this pocket is significantly longer for MMP-13, nearly reaching the surface of the protein. On the basis of the extended nature of the MMP-13 S1' pocket an inhibitor potent and selective for MMP-13 was designed from an initial high throughput screening (HTS) lead. CL-82198 was identified as a weak (10 μ M) inhibitor against MMP-13 while demonstrating no activity against MMP-1, MMP-9, or the related enzyme TACE. The drug-like properties of CL-82198 made it an ideal candidate for optimization of enzyme potency and selectivity. On the basis of NMR binding studies, it was shown that inhibitor CL-82198 bound

MMP-13 inhibitors

within the entire S1' pocket of MMP-13 which is the basis of its selectivity against MMP-1, MMP-9, and TACE. A strategy utilizing this information was devised for designing new inhibitors that showed enhanced selectivity toward MMP-13. Our design strategy combined the critical selectivity features of CL-82198 with the known potency features of a nonspecific MMP inhibitor (WAY-152177) to generate a potent and selective **MMP-13 inhibitor** (WAY-170523). WAY-170523 has an IC50 of 17 nM for MMP-13 and showed >5800-, 56-, and >500-fold selectivity against MMP-1, MMP-9, and TACE, resp.

AN 2000:662531 CAPLUS

DN 133:360381

TI Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design

AU Chen, James M.; Nelson, Frances C.; Levin, Jeremy I.; Mobilio, Dominick; Moy, Franklin J.; Nilakantan, Ramaswamy; Zask, Arie; Powers, Robert

CS Department of Biological Chemistry Wyeth Research, Wyeth Research, Cambridge, MA, 02140, USA

SO Journal of the American Chemical Society (2000), 122(40), 9648-9654

CODEN: JACSAT; ISSN: 0002-7863

PB American Chemical Society

DT Journal

LA English

RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials

AB We studied AG3340, a potent metalloproteinase (MMP) inhibitor with pM affinities for inhibiting gelatinases (MMP-2 and -9), MT-MMP-1 (MMP-14), and collagenase-3 (MMP-13) in many tumor models. AG3340 produced dose-dependent pharmacokinetics and was well tolerated after i.p. (i.p.) and oral dosing in mice. Across human tumor models, AG3340 produced profound tumor growth delays when dosing began early or late after tumor implantation, although all established tumor types did not respond to AG3340. A dose-response relationship was explored in three models: COLO-320DM colon, MV522 lung, and MDA-MB-435 breast. Dose-dependent inhibitions of tumor growth (over 12.5-200 mg/kg given twice daily, b.i.d.) were observed in the colon and lung models; and in a third (breast), maximal inhibitions were produced by the lowest dose of AG3340 (50 mg/kg, b.i.d.) that was tested. In another model, AG3340 (100 mg/kg, once daily, i.p.) markedly inhibited U87 glioma growth and increased animal survival. AG3340 also inhibited tumor growth and increased the survival of nude mice bearing androgen-independent PC-3 prostatic tumors. In a sixth model, KKLS gastric, AG3340 did not inhibit tumor growth but potentiated the efficacy of Taxol. Importantly, AG3340 markedly decreased tumor angiogenesis (as assessed by CD-31 staining) and cell proliferation (as assessed by bromodeoxyuridine incorporation), and increased tumor necrosis and apoptosis (as assessed by hematoxylin and eosin and TUNEL staining). These effects were model dependent, but angiogenesis was commonly inhibited. AG3340 had a superior therapeutic index to the cytotoxic agents, carboplatin and Taxol, in the MV522 lung cancer model. In combination, AG3340 enhanced the efficacy of these cytotoxic agents without altering drug tolerance. Addnl., AG3340 decreased the number of murine melanoma (B16-F10) lesions arising in the lung in an i.v. metastasis model when given in combination with carboplatin or Taxol. These studies directly support the use of AG3340 in front-line combination chemotherapy in ongoing clin. trials in patients with advanced malignancies of the lung and prostate.

AN 1999:473511 CAPLUS

DN 131:139010

TI Broad antitumor and antiangiogenic activities of AG3340, a potent and

MMP-13 inhibitors

selective MMP inhibitor undergoing advanced oncology clinical trials
 AU Shalinsky, D. R.; Brekken, J.; Zou, H.; McDermott, C. D.; Forsyth, P.;
 Edwards, D.; Margosiak, S.; Bender, S.; Truitt, G.; Wood, A.; Varki, N.
 M.; Appelt, K.
 CS Departments of Pharmacology, Agouron Pharmaceuticals, Inc., San Diego, CA,
 92121, USA
 SO Annals of the New York Academy of Sciences (1999),
 878(Inhibition of Matrix Metalloproteinases), 236-270
 CODEN: ANYAA9; ISSN: 0077-8923
 PB New York Academy of Sciences
 DT Journal
 LA English
 RE.CNT 72 THERE ARE 72 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 TI synthesis and identification of conformationally constrained selective MMP
 inhibitors
 AB A new series of potent conformationally constrained MMP inhibitors that
 are selective for MMP-13 over MMP-1 was discovered.
 AN 1999:429268 CAPLUS
 DN 131:199456
 TI synthesis and identification of conformationally constrained selective MMP
 inhibitors
 AU Freskos, John N.; McDonald, Joseph J.; Mischke, Brent V.; Mullins, Patrick
 B.; Shieh, Huey-Sheng; Stegeman, Roderick A.; Stevens, Anna M.
 CS Department of Medicinal Chemistry, Searle Discovery Research, St Louis,
 MO, 63198, USA
 SO Bioorganic & Medicinal Chemistry Letters (1999), 9(13),
 1757-1760
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	21.46	21.67
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.00	-3.00

FILE 'STNGUIDE' ENTERED AT 12:42:47 ON 30 MAR 2006
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
 AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
 LAST RELOADED: Mar 24, 2006 (20060324/UP).

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	21.73
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

MMP-13 inhibitors

	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-3.00

STN INTERNATIONAL LOGOFF AT 12:43:02 ON 30 MAR 2006